Bisphosphonate (zoledronic acid) associated adverse events: single center experience

GÖRÜMLÜ, Gürbüz; KARACA, ŞAZİYE BURÇAK; KÜÇÜKZEYBEK, Yüksel; USLU, Rüçhan; GÜL, M.KemaL; CENGİZ, Ercüment; ŞANLI, Ulus A.; ERTEN, Çiğdem; Karabulut, Bulent

Bisphosphonate (zoledronic acid) associated adverse events: single center experience

Yüksel KÜÇÜKZEYBEK, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

Gürbüz GÖRÜMLÜ, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

Ercüment CENGİZ, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

Çiğdem ERTEN, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

ŞAZİYE BURÇAK KARACA, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

M.KemaL GÜL, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

Bülent KARABULUT, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

Ulus A. ŞANLI, (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

Rüçhan USLU (Ege Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İzmir, Türkiye)

Uluslararası Hematoloji-Onkoloji Dergisi

4 0

Yıl: 2010 Cilt: 20 Sayı: 3 Sayfa Aralığı: 135 - 140 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Bisphosphonate (zoledronic acid) associated adverse events: single center experience

Öz:

Zoledronik asit kemik metastazı gelişen hastalarda kullanılan, etkinliği kanıtlanmış bifosfonattır. Çalışmamızda zoledronik asit kullanan hastalarda meydana gelen yan etkilerin değerlendirilmesi planlandı. Ocak 2001 ve ocak 2007 yılları arasında polik liniğe başvuran solid tümör tanılı toplam 5482 hastanın dosyası tarandı. İkiyüzellialtı hastada zoledronik asit kullanımı sap tandı. Zoledronik asit 4 mg 15 dakika intravenöz infüzyon şeklinde 21/28 günde bir uygulandı. Hastalarda meydana gelen yan etkiler olan, hipokalsemi, semptomatik hipokalsemi, böbrek fonksiyonlarında bozukluk, çene osteonekrozu retrospektif olarak değerlendirildi. Hastaların 248 inde kemik metastazı, 6 sında malign hiperkalsemi, 2 sinde osteoporoz nedeniyle zole- dronik asit başlanmıştı. Dört (1.5%) hastada çene osteonekrozu, 22 (8.5%) hastada hipokalsemi, 19 (7.4%) hastada böbrek fonksiyonlarında bozulma, 2 (0.7%) hastada semptomatik hipokalsemi saptandı. Zoledronik asit kemik metastazına bağlı gelişebilen, patolojik fraktür, spinal kord basısı, hiperkalsemi gibi komplikasyonların gelişimini azalttığı kanıtlanmış bifosfonattır. Diğer taraftan zoledronik asit kullanan hastalarda yanetkiler meydana gelebilmektedir. Zoledronik asit başlanması planlanan hastalara elde edilebilecek faydalar ve ortaya çıkabilecek yan etkiler ile ilgili bilgi verilmesi uygun olacaktır.

Anahtar Kelime:

Konular: Onkoloji

Bifosfonat (zoledronik asit) ilişkili yan etkiler: tek merkez deneyimi

Öz:

Zoledronic acid is an efficacy-proven bisphosphonate used in the patients who develop bone metastasis. In our study, we planned to evaluate side effects occurring in the patients who receive zoledronic acid. The records of a total of 5.482 patients diagnosed with solid tumor who were admitted to oncology out-patients’ clinic between January 2001 and January 2007 were scanned. It was found that 256 patients received zoledronic acid. Zoledronic acid is administered in 4 mg doses for a period of 15 minutes as intravenous infusion once in 21/28 days. Side effects such as hypocalcemia, symptomatic hypocal- cemia, impairment in renal functions and osteonecrosis of the jaw, were evaluated retrospectively. Zoledronic acid was administered due to bone metastasis in 248 patients, malign hypercalcemia in 6 patients and ostoporosis in 2 patients.Four patients (1.5%) were diagnosed with jaw osteonecrosis, 22 patients (8.5%) were diagnosed with hypocalcemia, 19 patients (7.4%) were diagnosed with impairment in renal functions, and 2 patients were (0.7%) diagnosed with symptomatic hypocalcemia. Zoledronic acid is a bisphosphonate which has been proven to reduce complications which may develop depending on the bone metastasis, such as pathological fracture, spinal chord impression andhypercalcemia. On the other hand, side effects may occur in the patients receiving zoledronic acid. It will be appropriate to inform the patients who are planned to start administering zoledronic acid of the benefits to be obtained and the side effects to take place.

Anahtar Kelime:

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24: 945-952, 2006.
2. Coleman RE. Metastatic bone disease: Clinical featu res, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176, 2001.
3. Berenson JR, Rajdev L, Broder M. Managing bone complications of solid tumors. Cancer Biol Ther 5: 1086-1089, 2006.
4. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16: 579-584, 2005.
5. Cheng EY. Prospective quality of life research in bony metastatic disease. Clin Orthop Relat Res (415 Suppl.): S289-297, 2003.
6. Russell RG, Bisaz S, Fleisch H, et al. Inorganic pyrop hosphate in plasma, urine, and synovial fluid of pati ents with pyrophosphate arthropathy (chondrocalcino sis or pseudogout). Lancet 2: 899-902, 1970.
7. Ibrahim A, Scher N, Williams G, et al. Approval sum mary for zoledronic acid for treatment of multiple mye loma and cancer bone metastases. Clin Cancer Res 9: 2394-2399, 2003.
8. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbi dity in metastatic cancer. BMJ 327: 469, 2003.
9. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961-2978, 2000.
10. Rogers MJ. New insights into the molecular mecha nisms of action of bisphosphonates. Curr Pharm Des 9: 2643-2658, 2003.
11. Marx RE. Pamidronate and zoledronate induced avas cular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117, 2003.
12. Sarin J, De Rossi SS, Akintoye SO. Updates on bisp hosphonates and potential pathobiology of bisphosp hanate-induced jaw osteonecrosis. Oral Disease 14: 277-285, 2008.
13. Edwards BJ, Gounder M, McKoy JM, et al. Pharma covigilance and reporting oversight in US FDA fast track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9: 1166-1172, 2008.
14. Bamias A, Kastritis E, Bamia C. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580- 8587, 2005.
15. Murad OM, Arora S, Farag AF, Guber HA. Bisphosp honates and osteonecrosis of the jaw: a retrospective study. Endocr Pract 13: 232-238, 2007.
16. Hellstein JW, Marek CL. Bisphosphonate osteoche monecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63: 682-689, 2005.
17. Woo SB, Hellstein JW, Kalmar JR, et al. Systematic re view: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761, 2006.
18. La Verde N, Bareggi C, Grassino M, et al. Osteonec rosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenome non can change its evolution. Support Care Cancer 16: 1311-1315, 2008.
19. Khosla S, Burr D, Cauley J, et al. Bisphosphonate as sociated osteonecrosis of the jaw: report of a task for ce of the american society for bone and mineral rese arch. J Bone Miner Res 22: 1479-1491, 2007.
20. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxil lofac Surg 62: 527–34, 2004.
21. Ruggiero SL, FantasiaJ, Carlson E. Bisphosphonates related osteonecrosis of the jaw: background and gu idelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 433-441, 2006.
22. Ruggiero S, Gralow J, Marx RE, et al. Practical guide lines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J On col Pract 2: 7-14, 2006.
23. Chang JT, Gren L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676-1678, 2003.
24. Papapetrou PD. Bisphosphonates associated adverse events.Hormones (Athens). 8: 96-110, 2009.
25. Perazella MA, Markowitz GS. Bisphosphonate neph rotoxicity. Kidney Int 74:1385-1393, 2008.
26. McDermott RS, Kloth DD, Wang H, et al. Impact of zo ledronic acid on renalfunction in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 4: 524-529, 2006.
27. Bergner R, Diel IJ, Henrich D, et al. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. On kologie 29: 534-540, 2006.
28. Balla J. The issue of renal safety of zoledronic acid from a nephrologist’s point of view. Oncologist 10: 306-308, 2005.
29. Hillner BE, Ingle JN, Chlebowski RT, et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042-4057, 2003.
30. Weinman EJ, Patak RV. Acute renal failure in cancer patients. Oncology (Huntingt) 6: 47-52, 1992.
31. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate. Kidney Int. 64: 281-289, 2003.
32. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042-4057, 2003.
33. Chennuru S, Koduri J, Baumann MA. Risk factors for symtomatic hypocalcemia complicating treatment with zoledronic acid. Intern Med J 38: 635-637, 2008.
34. Schussheim DH, Jacobs TP, Silverberg SJ. Hypocal cemia associated with alendronate. Ann Intern Med 130: 329, 1999.
35. Malouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr pract 12: 48-53, 2006.
36. Macisaac RJ, Seeman E, Herums G. Seizures after alendronate. J Royal Soc Med 95: 615-616, 2002.
37. Henley D, Kaye J, Walsh J, Cull G. Symptomatic hypocalcemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Intern Med J 35: 726-728, 2005.

APA	KÜÇÜKZEYBEK Y, GÖRÜMLÜ G, CENGİZ E, ERTEN Ç, KARACA Ş, GÜL M, Karabulut B, ŞANLI U, USLU R (2010). Bisphosphonate (zoledronic acid) associated adverse events: single center experience. , 135 - 140.
Chicago	KÜÇÜKZEYBEK Yüksel,GÖRÜMLÜ Gürbüz,CENGİZ Ercüment,ERTEN Çiğdem,KARACA ŞAZİYE BURÇAK,GÜL M.KemaL,Karabulut Bulent,ŞANLI Ulus A.,USLU Rüçhan Bisphosphonate (zoledronic acid) associated adverse events: single center experience. (2010): 135 - 140.
MLA	KÜÇÜKZEYBEK Yüksel,GÖRÜMLÜ Gürbüz,CENGİZ Ercüment,ERTEN Çiğdem,KARACA ŞAZİYE BURÇAK,GÜL M.KemaL,Karabulut Bulent,ŞANLI Ulus A.,USLU Rüçhan Bisphosphonate (zoledronic acid) associated adverse events: single center experience. , 2010, ss.135 - 140.
AMA	KÜÇÜKZEYBEK Y,GÖRÜMLÜ G,CENGİZ E,ERTEN Ç,KARACA Ş,GÜL M,Karabulut B,ŞANLI U,USLU R Bisphosphonate (zoledronic acid) associated adverse events: single center experience. . 2010; 135 - 140.
Vancouver	KÜÇÜKZEYBEK Y,GÖRÜMLÜ G,CENGİZ E,ERTEN Ç,KARACA Ş,GÜL M,Karabulut B,ŞANLI U,USLU R Bisphosphonate (zoledronic acid) associated adverse events: single center experience. . 2010; 135 - 140.
IEEE	KÜÇÜKZEYBEK Y,GÖRÜMLÜ G,CENGİZ E,ERTEN Ç,KARACA Ş,GÜL M,Karabulut B,ŞANLI U,USLU R "Bisphosphonate (zoledronic acid) associated adverse events: single center experience." , ss.135 - 140, 2010.
ISNAD	KÜÇÜKZEYBEK, Yüksel vd. "Bisphosphonate (zoledronic acid) associated adverse events: single center experience". (2010), 135-140.

APA	KÜÇÜKZEYBEK Y, GÖRÜMLÜ G, CENGİZ E, ERTEN Ç, KARACA Ş, GÜL M, Karabulut B, ŞANLI U, USLU R (2010). Bisphosphonate (zoledronic acid) associated adverse events: single center experience. Uluslararası Hematoloji-Onkoloji Dergisi, 20(3), 135 - 140.
Chicago	KÜÇÜKZEYBEK Yüksel,GÖRÜMLÜ Gürbüz,CENGİZ Ercüment,ERTEN Çiğdem,KARACA ŞAZİYE BURÇAK,GÜL M.KemaL,Karabulut Bulent,ŞANLI Ulus A.,USLU Rüçhan Bisphosphonate (zoledronic acid) associated adverse events: single center experience. Uluslararası Hematoloji-Onkoloji Dergisi 20, no.3 (2010): 135 - 140.
MLA	KÜÇÜKZEYBEK Yüksel,GÖRÜMLÜ Gürbüz,CENGİZ Ercüment,ERTEN Çiğdem,KARACA ŞAZİYE BURÇAK,GÜL M.KemaL,Karabulut Bulent,ŞANLI Ulus A.,USLU Rüçhan Bisphosphonate (zoledronic acid) associated adverse events: single center experience. Uluslararası Hematoloji-Onkoloji Dergisi, vol.20, no.3, 2010, ss.135 - 140.
AMA	KÜÇÜKZEYBEK Y,GÖRÜMLÜ G,CENGİZ E,ERTEN Ç,KARACA Ş,GÜL M,Karabulut B,ŞANLI U,USLU R Bisphosphonate (zoledronic acid) associated adverse events: single center experience. Uluslararası Hematoloji-Onkoloji Dergisi. 2010; 20(3): 135 - 140.
Vancouver	KÜÇÜKZEYBEK Y,GÖRÜMLÜ G,CENGİZ E,ERTEN Ç,KARACA Ş,GÜL M,Karabulut B,ŞANLI U,USLU R Bisphosphonate (zoledronic acid) associated adverse events: single center experience. Uluslararası Hematoloji-Onkoloji Dergisi. 2010; 20(3): 135 - 140.
IEEE	KÜÇÜKZEYBEK Y,GÖRÜMLÜ G,CENGİZ E,ERTEN Ç,KARACA Ş,GÜL M,Karabulut B,ŞANLI U,USLU R "Bisphosphonate (zoledronic acid) associated adverse events: single center experience." Uluslararası Hematoloji-Onkoloji Dergisi, 20, ss.135 - 140, 2010.
ISNAD	KÜÇÜKZEYBEK, Yüksel vd. "Bisphosphonate (zoledronic acid) associated adverse events: single center experience". Uluslararası Hematoloji-Onkoloji Dergisi 20/3 (2010), 135-140.